23rd week of 2011 patent applcation highlights part 52 |
Patent application number | Title | Published |
20110136797 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR - Certain cyclopropyl amines are histamine H | 2011-06-09 |
20110136798 | Crystalline Forms Of A Pyridine Derivative - The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) | 2011-06-09 |
20110136799 | PROLINE DERIVATIVES - Compounds of formula (I): | 2011-06-09 |
20110136800 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE - The present invention relates to compounds defined by formula I | 2011-06-09 |
20110136801 | Novel Compounds - The present invention provides compounds of formula (I): | 2011-06-09 |
20110136802 | SHIP1 MODULATORS AND METHODS RELATED THERETO - Compounds of structure (I): | 2011-06-09 |
20110136803 | Triazolophthalazines - The compounds of formula (I) | 2011-06-09 |
20110136804 | Nicotinic Acetylcholine Receptor Ligands 101 - Nicotinic acetylcholine receptor ligands of Formula I | 2011-06-09 |
20110136805 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION OF SAME - The present invention relates to bicyclic heterocycles of general formula | 2011-06-09 |
20110136806 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof - The invention relates to bicyclic heterocycles of general formula (I), in which R | 2011-06-09 |
20110136807 | Bicyclic compositions and methods for modulating a kinase cascade - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. | 2011-06-09 |
20110136808 | 3',6-SUBSTITUTED INDIRUBINS AND THEIR BIOLOGICAL APPLICATIONS - Indirubin derivatives of formula (I) wherein R represents -(A) | 2011-06-09 |
20110136809 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer - The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I). | 2011-06-09 |
20110136810 | ANTITUMOR AGENT, KIT AND METHOD OF TREATING CANCER - Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer. | 2011-06-09 |
20110136811 | PROKINETICIN 1 RECEPTOR - The present invention relates to methods of monitoring the biological activity of the PK1 receptor. | 2011-06-09 |
20110136812 | SOLUBILIZED TOPOISOMERASE POISONS - The invention provides compounds of formula I: | 2011-06-09 |
20110136813 | WNT PROTEIN SIGNALLING INHIBITORS - The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis. | 2011-06-09 |
20110136814 | Diazepine and Diazocane Compounds As MC4 Agonists - The present invention relates to compounds of formula (I) wherein R | 2011-06-09 |
20110136815 | SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME - Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix. | 2011-06-09 |
20110136816 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2011-06-09 |
20110136817 | Methods of identifying responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites:dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy. | 2011-06-09 |
20110136818 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN - The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. | 2011-06-09 |
20110136819 | 6-THIOXOPYRIDAZINE DERIVATIVES - Compounds of the formula I, in which R | 2011-06-09 |
20110136820 | Heterocyclic Compounds as CCR2 Antagonists - Compounds of formula (I) | 2011-06-09 |
20110136821 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 - This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I). | 2011-06-09 |
20110136822 | CERTAIN CRYSTALLINE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE THEREOF - At least one crystalline hydrate of (S)—[N-3-(3′-fluoro-4′-(4″-phenyl piperazinyl))phenyl-2-oxo-5-oxazolidinyl]methyl acetamide, such as those with the following formula: | 2011-06-09 |
20110136823 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF - The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy. | 2011-06-09 |
20110136824 | UROTENSIN II RECEPTOR ANTAGONISTS - The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described. | 2011-06-09 |
20110136825 | Treatment of Vasomotor Symptoms - The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin. | 2011-06-09 |
20110136826 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2011-06-09 |
20110136827 | Bis-Acylated Hydroxylamine Derivatives - The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy. | 2011-06-09 |
20110136828 | SUBSTITUTED N-OXIDE PYRAZINE DERIVATIVES - N-oxide pyrazine derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 2011-06-09 |
20110136829 | 3-(N-HETEROCYCLYL)-PYRROLIDINYL-PHENYL-OXAZOLIDINONES AS ANTIBACTERIAL AGENTS - The invention provides new oxazolidinone compounds of formula (I) wherein R, R | 2011-06-09 |
20110136830 | CHROMENONE DERIVATIVES - Novel compounds of the formula I | 2011-06-09 |
20110136831 | N-2-(Hetero)Arylethylcarboxamide Derivative, and Pest-Controlling Agent Comprising the Same - An N-2-(hetero)arylethylcarboxamide derivative represented by the formula (I) | 2011-06-09 |
20110136832 | Promoting Cycling of ApoE4 Isoform - Cycling of ApoE4 isoform is promoted in a person in need thereof by contacting the person with an effective amount of a pharmaceutically-acceptable modulator of intracellular ApoE4 transport vesicle pH. | 2011-06-09 |
20110136833 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof - The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R | 2011-06-09 |
20110136834 | INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2011-06-09 |
20110136835 | COMBINATION FORMULATIONS OF TRANILAST AND ALLOPURINOL AND METHODS RELATED THERETO - Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable salt thereof in said composition. | 2011-06-09 |
20110136836 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders - This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin. | 2011-06-09 |
20110136837 | MUCOADHESIVE BUCCAL TABLETS FOR THE TREATMENT OF OROFACIAL HERPES - The present invention relates to the treatment or prevention of muco-cutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes. | 2011-06-09 |
20110136838 | CHEMICAL COMPOUNDS - The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: | 2011-06-09 |
20110136839 | COMBINATION OF TWO ANALGESIC CHEMICALS - The present invention is a novel analgesic combination and its use. It is classified to he an invention in the field of medicine and technology. The purpose of this invention is to solve the problem that existing analgesics does not effectively attenuate pain or produces serious side-effects in clinic. The ingredients of the analgesic combination include ketanserin and propranolol. This combination is used to make a drug to treat pain. Because the ingredients of the analgesic combination target peripheral receptors, the unwanted effects could be only minimal. The big advantage of this combination is that each of the ingredients acts on the different receptors producing the synergizing analgesic. Therefore, the analgesia that the combination produces is remarkable and the effective doses are low. | 2011-06-09 |
20110136840 | ANTI-INFECTIVE AGENTS - The present invention relates to the use of molecules having a spacer unit, linker and recognition unit(s) for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in preventing or treating infectious diseases and diseases, disorders or conditions related thereto. Further, the present invention relates to methods for preventing or treating diseases, disorders or conditions involving recognition and binding of carbohydrate structures. | 2011-06-09 |
20110136841 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2011-06-09 |
20110136842 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers - A series of disubstituted dihydroisoquinolinone and isoquinolinedione derivatives represented by Formula I, or pharmaceutically acceptable salts thereof are presented. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 2011-06-09 |
20110136843 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma - The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases. | 2011-06-09 |
20110136844 | METHODS FOR INHIBITING DYRK1A TO TREAT CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - Compositions and methods for treating, preventing and/or delaying the onset and/or the development of diseases and disorders of the central nervous system are disclosed. The present disclosure relates to indoloquinoline compounds that are capable of inhibiting at least one protein kinase, and to methods for preparing and uses of such compounds. The compounds described herein are administered to patients to achieve a therapeutic effect. | 2011-06-09 |
20110136845 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof - The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain. | 2011-06-09 |
20110136846 | Buprenorphine Analogs - The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II or Formula III shown below, wherein R | 2011-06-09 |
20110136848 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF DRUG OVERDOSE - The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose: | 2011-06-09 |
20110136849 | PROCESS FOR REDUCING CONTAMINATING MICHAEL ACCEPTOR LEVELS IN OXYCODONE AND OTHER COMPOSITIONS - The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors. | 2011-06-09 |
20110136850 | METHODS AND COMPOSITIONS FOR TOPOISOMERASE I MODULATED TUMOR SUPPRESSION - Disclosed herein are methods and compositions for determining the sensitivity or enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing cell death, apoptosis and/or growth arrest which may be used for tumor suppression. | 2011-06-09 |
20110136851 | Sucralose Formulations To Mask Unpleasant Tastes - The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH from about 2 to about 5. The invention is further directed to medicinal compositions comprising such a liquid excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liquid excipient bases. | 2011-06-09 |
20110136852 | Rapamycin Derivative or an Impdh Inhibitor for Treating Polycystic Kidney Disease - A method for treating polycystic kidney disease, comprising administering to a subject in need thereof a therapeutical effective amount of an inosine-5′-monophosphate dehydrogenase inhibitor or a rapamycin derivative. | 2011-06-09 |
20110136853 | LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT - The present invention is directed to the novel ligand with wide range of pharmacological activity including activity to GPCR receptors, ion channels and monoamine transporters representing 3-methyl-9-benzyl-1,2,3,4-tetrahydrocarboline naphthalene-1,5-disulfonate of formula 1 | 2011-06-09 |
20110136854 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-06-09 |
20110136855 | GEMIFLOXACIN PROCESS AND POLYMORPHS - The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also relates to infusion solutions of gemifloxacin and to processes for their preparation. Thus, 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphth-yridine-3-carboxylic acid is reacted with a mixture of acetic anhydride, acetic acid and boric acid to give borane compound, which is then treated with 4-Aminomethyl-3-methoxyimino-pyrrolidinium dimethanesulfonate in presence of triethylamine, followed by treatment with 3.5% sodium hydroxide solution to give gemifloxacin free base. | 2011-06-09 |
20110136856 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same - The invention concerns compounds of formula I, a method for preparing said compounds, pharmaceutical compositions containing same and the theraprutic uses thereof. | 2011-06-09 |
20110136857 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them. | 2011-06-09 |
20110136858 | Preferred Combination Therapy - Composition and use of a medicament comprising a fixed dose combination of droloxifene and clopidogrel, or the pharmaceutically acceptable salts thereof, for treating or preventing a disorder associated with the loss of normal adult tissue architecture. | 2011-06-09 |
20110136859 | Compounds - A compound of formula (I) | 2011-06-09 |
20110136860 | Compounds - A compound of formula (I): | 2011-06-09 |
20110136861 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 - The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof. | 2011-06-09 |
20110136862 | NOVEL TETRAMETHYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel tetramethyl substituted pipehdine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-06-09 |
20110136863 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-06-09 |
20110136864 | TETRAHYDROQUINOLINE INDOLE DERIVATIVES AND USES THEREOF - Compounds of the formula: | 2011-06-09 |
20110136865 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists - The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds. | 2011-06-09 |
20110136866 | INSECTICIDAL PHENYL- OR PYRIDYL-PIPERDINE COMPOUNDS - A compound of formula (I): wherein A, p, R | 2011-06-09 |
20110136867 | Treatment of Synucleinopathies - Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, and Multiple System Atrophy, or other neurodegenerative diseases are provided. The treatment including administering to a subject a farnesyl transferase inhibitor compound. | 2011-06-09 |
20110136868 | AGENTS FOR INHIBITING OSTEOCLASTOGENESIS AND/OR OSTEOCLAST ACTIVATION - Agents, which are both ceramide glucosyltransferase inhibitors and glucosidase inhibitors, may inhibit osteoclastogenesis and/or reduce osteoclast activation and, therefore, may be useful for osteolytic activity and bone loss in subjects with conditions, such as multiple myeloma. | 2011-06-09 |
20110136869 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 2011-06-09 |
20110136870 | GACYCLIDINE FORMULATIONS - Improved formulations of gacyclidine for direct administration to the inner or middle ear. | 2011-06-09 |
20110136871 | 2-ALKOXY-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE - The present application relates to novel 2-alkoxy-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders. | 2011-06-09 |
20110136872 | STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF - The present invention is based on the discovery that a marked increase in aqueous stability (and thereby shelf life) of prostanoid agonist prodrug compositions is achieved by incorporating into the compositions certain well-defined carboxylic acids, and thereafter adjusting the pH of the compositions from about 4.0 to about 8.0. As a result, the compositions and methods of the invention provide the aqueous stability required for marketable topical drug treatments of a wide variety of ocular disorders. | 2011-06-09 |
20110136873 | Inhibitors of Cyclin Dependent Kinases and Their Use - The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), | 2011-06-09 |
20110136874 | FUNGICIDAL N-(2-PYRIDYLPROPYL) CARBOXAMIDE DERIVATIVES AND THEIR OXA, AZA AND THIA ANALOGUES - The present invention relates to fungicide N-(2-pyridylpropyl)carboxamide derivative and its oxa, aza and thia analogues of formula (I), their process of preparation and intermediate compound for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2011-06-09 |
20110136875 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2011-06-09 |
20110136876 | Altering Pharmacokinetics of Pirfenidone Therapy - The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. | 2011-06-09 |
20110136877 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS - The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I): | 2011-06-09 |
20110136878 | AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE, AND PEST CONTROLLING METHOD - A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(=G | 2011-06-09 |
20110136879 | COMPOUND - The invention provides compounds of formula (I) | 2011-06-09 |
20110136880 | Latrunculin-Based Macrolides and Their Uses - Latrunculin derivatives are disclosed, as are anti-invasive and cytotoxic uses for latrunculins and latrunculin derivatives, and semisyntheses of latrunculin derivatives. The latrunculins and latrunculin derivatives are useful, for example, in treating cancers. | 2011-06-09 |
20110136881 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2011-06-09 |
20110136882 | MICROBIOCIDAL CONTROL IN THE PROCESSING OF MEAT-PRODUCING FOUR-LEGGED ANIMALS - Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise I) contacting exterior surfaces of the live animal at least once with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one N,N′-bromochloro-5,5-dialkylhydantoin, such contacting occurring at least once when the animal is en route to being slaughtered but before it is killed by exsanguination; or II) contacting the carcass of the animal, after exsanguination, with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one N,N′-bromochloro-5,5-dialkylhydantoin or III) contacting at least one raw meat product and/or at least one processed meat product derived from the carcass. The contacting can be done one or more times in each of I), II), and III). Considerable advantages, which are described, are realized when using such methods. | 2011-06-09 |
20110136883 | GRANULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention discloses a dry formulation or granulation comprising, in admixture, more than 50 wt. % of active pharmaceutical ingredient and from 1 to 10 wt. % of each of any nonaqueous excipient selected from liquid substances. In a preferred embodiment no water or lower alcohol has been added in any step of the preparation of the dry formulation or granulation, and the nonaqueous excipient selected from liquid substances is adsorbed to dryness by the active pharmaceutical ingredient and/or by a further solid excipient. Pharmaceutical formulations based on such dry formulation or granulation, and processes for the preparation thereof, are described as well. The dry formulations or granulations reliably and effectively further processed under dry conditions without requiring active drying, including e.g. briquetting, slugging, sieving, milling, tabletting, further fine granulating, direct compression, and the like. | 2011-06-09 |
20110136884 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF - The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders. | 2011-06-09 |
20110136885 | Synergistic Combination of Analgesic Compounds - The present invention relates to a pharmaceutical composition comprising as active substances:
| 2011-06-09 |
20110136886 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2011-06-09 |
20110136887 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists - The invention relates to compounds of Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including antagonism of Prostaglandin EP4 receptor as a therapeutic treatment. | 2011-06-09 |
20110136888 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof - The present invention involves substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, in particular in the fields of human and animal health. | 2011-06-09 |
20110136889 | COMPOSITIONS AND THEIR USES DIRECTED TO ACEYTL-COA CARBOXYLASES - Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. | 2011-06-09 |
20110136890 | TREATMENT OF FIBROTIC CONDITIONS - Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles. | 2011-06-09 |
20110136891 | Nucleic acid molecules and collections thereof, their application and Identification - Provided is a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) as disclosed herein or a mammalian ortholog thereof and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides new nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof. | 2011-06-09 |
20110136892 | Targeting TGF-beta as a Therapy for Alzheimer's Disease - The invention includes compositions and methods for enhancing peripheral macrophage Aβ phagocytosis activity. The invention includes inhibiting a component of TGF-β signaling pathway in peripheral macrophages to promote central nervous system infiltration and beneficial cerebral Aβ clearance. Inhibition of TGF-β signaling in peripheral macrophages represents an advantageous anti-amyloid therapeutic approach for Alzheimer's disease. | 2011-06-09 |
20110136893 | OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES - A conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5′-end of the oligonucleotide and at least one polyethyleneglycol is linked to the 3′-end of the oligonucleotide, wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is identical and is <5000 Da, or wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the oligonucleotide is different. | 2011-06-09 |
20110136894 | Shortened Alk1 Regulatory Fragment - Regulatory elements for controlling expression of transgenes in angiogenic tissue are provided. One embodiment provides an isolated nucleic acid having at least 80%, 85%, 90%, 95%, 97%, 99% or 100% sequence identity to SEQ ID NO:1, or a fragment thereof that causes expression of a transgene in angiogenic tissue. Vectors containing SEQ ID NO:1 and one or more transgenes are also provided. A preferred vector is an adenovirus vector. The transgene can encode a cytotoxin, pro-apoptotic polypeptide, or a therapeutic polypeptide. SEQ ID NO:1 regulates the expression of the transgene such that the transgene is only expressed in angiogenic tissue including, but not limited to arteries feeding ischemic tissues. Methods of using vectors containing SEQ ID NO:1 are also provided. | 2011-06-09 |
20110136895 | Methods and compositions for modulating PD1 - Disclosed herein are methods and compositions for modulating expression of a PD1 gene. | 2011-06-09 |
20110136896 | VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF - The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine. | 2011-06-09 |
20110136897 | TOLL-LIKE RECEPTOR 9 AGONISTS FOR THE TREATMENT OF ANXIETY-RELATED DISORDERS AND INFLAMMATORY DISORDERS - Uses of TLR-9 agonists are disclosed. The uses include treatment of anxiety-related disorders and inflammatory disorders. For treatment of inflammatory disorders the TLR-9 agonists are administered together with a therapeutically effective amount of a glucocorticoid. | 2011-06-09 |